J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
GSK's depemokimab gets EMA nod for asthma and nasal polyps
GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.29 billion and currently ...
GSK's depemokimab under review in China and Japan for asthma, CRSwNP
GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...
UBS Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...
New cancer vaccine will 'stop disease before it takes hold'
The partnership between the pharmaceutical giant and the university aims to create a vaccine or vaccines which target cells ...
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...
FiercePharma1d
Amid more drug-price scrutiny, biopharma companies largely keep their January hikes in check
As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...
‘Shark’ pharmaceutical companies not being honest about side effects, MPs warned
MHRA’s independence also questioned during Commons debate, with regulator accused of being too close to companies it ...
Business Today7d
Glaxosmithkline Pharmaceuticals Ltd (GLAXO) Share Price
No Data For Bulk Deal. *Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline ...